-
FDA postpones decision on Pfizer RA drug, citing time needed to review new data
NEW YORK — The Food and Drug Administration has postponed its decision whether or not to approve an experimental arthritis drug made by Pfizer, the drug maker said.
Pfizer said the FDA had extended its action date for the drug tofacitinib by three months, to Nov. 21, because additional analyses of data that the company submitted constituted a "major amendment" to Pfizer's regulatory application and will require additional time to review.
-
Mission Pharmacal promoting Lycelle lice kit for BTS season
SAN ANTONIO — Mission Pharmacal will "aggressively" market its head lice kit during the back-to-school season, the company said Wednesday.
The company said it would market the prescription Lycelle kit for the season, when lice infestations are often most rampant. The kit is a drug- and pesticide-free way of eliminating lice and nits that requires a single, 10-minute application.